Provider: View Press Release
Type: Link
Title: GSK launches £6m programme to boost STEM career progression for young people from under-represented groups in the UK | GSK
Description: GSK to invest £6m in STEM equity-focused initiatives in the UK over ten years to tackle barriers to entry in STEM careers.
Provider: View Press Release
Type: Link
Title: ViiV Healthcare receives approval from China’s National Medical Products Administration (NMPA) for Vocabria (cabotegravir) used in combination with Rekambys (rilpivirine), the first and only complete long-acting HIV-1 injectable treatment | GSK
Description: The complete long-acting regimen enables virologically suppressed people living with HIV in China to reduce treatment dosing days.
Provider: View Press Release
Type: Link
Title: New data for Arexvy, GSK’s RSV vaccine, show potential to help protect adults aged 50 to 59 at increased risk for RSV disease | GSK
Description: Preliminary results from phase III trial show primary endpoints met, with non-inferior immune responses observed in adults aged 50-59.
Provider: View Press Release
Type: Link
Title: GSK enters exclusive license agreement with Hansoh for HS-20089 | GSK
Description: Hansoh’s HS-20089 complements GSK’s portfolio of gynaecologic cancer therapies.
Provider: View Press Release
Type: Link
Title: ViiV Healthcare to present 23 abstracts from innovative HIV treatment and prevention portfolio at EACS 2023 | GSK
Description: Key data to be presented include long-term and real-world data, including long-acting and 2-drug regimens.
Provider: View Press Release
Type: Link
Title: GSK highlights new data in non-small cell lung cancer and endometrial cancer at the European Society for Medical Oncology (ESMO) Congress 2023, reinforcing potential of Jemperli (dostarlimab) as a backbone immuno-oncology therapy | GSK
Description: Late-breaking data from head-to-head PERLA trial shows favourable numerical trend in overall survival (OS) results